**** SUPREMO has now closed to recruitment ****
MRC SUPREMO - a Phase III randomised trial to assess the role of adjuvant chest wall irradiation in intermediate risk breast cancer after mastectomy.
Following on from previous correspondence, we are writing to confirm that the SUPREMO trial has now closed to recruitment - 30th April 2013 at 5.00pm.
We would like to take this opportunity to thank the national and international investigators, patients, trial support staff, TMG, TSC and DMEC for their support in enabling us to reach our accrual target for the BIG 2-04 MRC/EORTC SUPREMO trial. This is a magnificent international cooperative effort to answer an important scientific question in breast cancer.
We would like to acknowledge support from the Breast International Group (BIG) and our funding bodies: the UK Medical Research Council, the EORTC, Cancer Australia, the William and Elizabeth Davies Charitable Trust and the Peter Chan Jee Yat Foundation and the Yeung Ying Yin and May Yeung Foundation.
Your hard work and commitment to the SUPREMO trial is appreciated.
Professor Ian Kunkler, Chief Investigator
Dr Peter Canney, Co-Chief Investigator
MRC/EORTC SUPREMO trial
If sites have any questions regarding the trial, please do not hesitate to contact a member of the Supremo trial team on email@example.com.
Correct CRF versions
Sites are reminded that patients who were consented to protocol versions 26 and 27 should continue to use version 1 CRFs, dated April 2006 and not to use version 2 CRFs, dated November 2010. Version 2 CRFs should only be used for patients who have consented to the current version of the protocol, version 29. All UK sites have now received V29 approval.